Abstract

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States

Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M

Issue: May/Jun 2006 - Hormone Replacement Therapy

Page(s): 175-183

Download in electronic PDF format for $75
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 1
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 2
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 3
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 4
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 5
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 6
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 7
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 8
  • The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Page 9

Abstract

Prior to 1980, almost all drug advertising was directed to physicians, the parties responsible for prescribing medications to patients. Beginning in 1980, however, drug companies began advertising directly to patients by various means, specifically television and print advertisements and sponsorship of sports and similar events. During the last decade, as computers have become a common household item, the Internet is now another source of advertising for drug manufacturers. This change in advertising has been effective, since research has demonstrated that physicians’ prescribing decisions are, in fact, influenced heavily by patients’ requests for specific medications. In 1997, the US Food and Drug Administration devised specific guidelines for the television advertising of drugs produced by pharmaceutical manufacturers. Since youth and beauty have long been valued feminine qualities in the US, where menopausal women are assumed to suffer most from the effects of aging, pharmaceutical companies targeted women

Related Keywords

  • drug advertising
  • drug promotion
  • commercials
  • hormone replacement therapy
  • HRT
  • US Food and Drug Administration
  • FDA
  • women
  • aging
  • drug marketing

Related Categories

  • HRT
  • LEGAL
  • MARKETING
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2006
Pg. 175-183
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 250-256
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Author(s): Gillson George R, Zava David T
Jan/Feb 2001
Pg. 52-54
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Author(s): Ford Gina, Garcia Lea
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Sep/Oct 2016
Pg. 359-364
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Author(s): Deleruyelle Laura J
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Nov/Dec 2016
Pg. 447-454
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Author(s): Deleruyelle Laura J
Jan/Feb 2020
Pg. 30-36
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Author(s): Dillon L R
Nov/Dec 2011
Pg. 526-527
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Author(s): Williams LaVonn A
Nov/Dec 2023
Pg. 474-481
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Jul/Aug 2022
Pg. 298-301
The Role of Compounding Pharmacists During Drug Shortages
Author(s): Ofei Kelvin
Jul/Aug 2007
Pg. 326-327
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Author(s): Kupiec Tom, Kemp Jesse
Jul/Aug 2007
Pg. 278-281
The Politics of Hormone Replacement Therapy
Author(s): Allen Loyd V Jr
Jan/Feb 2002
Pg. 50-54
Bioidentical Hormone Replacement Therapy, Part 2, A Review of
Author(s): Wepfer Scott T